felin
infecti
periton
fip
system
fatal
viralinduc
immunemedi
diseas
cat
caus
felin
infecti
periton
viru
fipv
mefloquin
human
antimalari
agent
shown
inhibit
fipv
vitro
first
step
evalu
efficaci
safeti
profil
potenti
fip
treatment
cat
mefloquin
underw
incub
felin
canin
common
brushtail
possum
microsom
phase
metabol
cofactor
determin
rate
phase
deplet
tramadol
use
phase
posit
control
undergo
reaction
dog
cat
use
substrat
deplet
method
vitro
intrins
clearanc
mean
sd
mefloquin
pool
felin
common
brushtail
possum
microsom
protein
respect
howev
phase
intrins
clearanc
slow
determin
canin
microsom
liquid
chromatographymass
spectrometri
lcm
identifi
carboxymefloquin
sampl
gener
felin
microsom
well
neg
control
suggest
mefloquin
instabl
mefloquin
also
underw
incub
felin
canin
common
brushtail
possum
microsom
phase
ii
glucuronid
metabol
cofactor
odesmethyltramadol
odmt
use
posit
control
undergo
phase
ii
glucuronid
reaction
speci
rate
phase
ii
mefloquin
deplet
microsom
three
speci
slow
estim
therefor
mefloquin
like
undergo
phase
hepat
metabol
catalys
felin
common
brushtail
possum
microsom
phase
ii
glucuronid
metabol
three
speci
mefloquin
like
delay
elimin
cat
clinic
normal
hepat
function
citat
ize
kimbl
b
norri
jm
govendir
vitro
hepat
metabol
mefloquin
use
microsom
cat
dog
common
brushtail
possum
trichosuru
vulpecula
plo
one
http
doi
felin
infecti
periton
system
fatal
viralinduc
immunemedi
diseas
primarili
affect
younger
cat
caus
virul
biotyp
felin
coronavirus
fcov
known
fipv
previous
use
therapi
fip
either
reli
immunosuppress
agent
dampen
clinic
sign
temporarili
attempt
repurpos
human
antivir
treatment
neither
approach
achiev
last
success
recent
therapeut
drug
identifi
address
underli
problem
felin
coronaviru
replic
howev
veterinari
access
antivir
treatment
current
problemat
consequ
addit
inexpens
safe
antivir
treatment
access
prescript
requir
investig
potenti
treat
fipv
infect
cat
demand
efficaci
antivir
fipv
crucial
reduc
clinic
diseas
minim
advers
effect
well
potenti
prevent
individu
treatment
select
viral
resist
antimalari
drug
mefloquin
current
use
prevent
monotherapi
treatment
either
alon
combin
artesun
chloroquineresist
plasmodium
falciparum
malaria
human
found
substanti
reduc
viral
load
fipv
felin
caliciviru
fcv
low
concentr
infect
crandel
ree
felin
kidney
cell
without
cytotox
effect
observ
suggest
mefloquin
may
use
administ
cat
fip
fcv
relat
diseas
howev
mefloquin
undergo
substanti
hepat
metabol
peopl
cat
lack
sever
major
phenol
udpglucuronosyltransferas
ugt
enzym
requir
phase
ii
glucuronid
metabol
prudent
obtain
inform
mefloquin
intrins
clearanc
cat
conduct
clinic
trial
live
anim
although
mani
model
assess
vitro
metabol
microsom
contain
mani
hepat
metabol
enzym
therefor
aim
studi
ascertain
mefloquin
vitro
intrins
clearanc
vitro
cl
int
incub
felin
hepat
microsom
respect
phase
eg
oxid
hydrolysi
reduct
reaction
phase
ii
eg
conjug
glucuronid
metabol
likewis
mefloquin
also
incub
canin
microsom
phase
phase
ii
metabol
reaction
order
compar
rate
vitro
clearanc
mefloquin
felin
canin
microsom
mefloquin
phase
metabol
canin
microsom
previous
report
contrast
cat
dog
known
experi
delay
phase
ii
conjug
metabol
mefloquin
also
incub
microsom
common
brushtail
possum
trichosuru
vulpecula
speci
possum
recognis
rapid
xenobiot
metabolis
mefloquin
verapamil
intern
standard
high
pressur
liquid
chromatographi
hplc
tramadol
hydrochlorid
odmt
phase
enzym
cofactor
adenin
dinucleotid
phosphat
sodium
nadp
glucos
catalyt
enzym
glucos
dehydrogenas
phase
ii
enzym
cofactor
uridin
acid
disodium
salt
udpga
alamethicin
poreform
peptid
antibiot
use
enhanc
cofactor
avail
purchas
sigmaaldrich
castl
hill
nsw
australia
hplc
grade
acetonitril
hplc
grade
methanol
ethyl
acet
purchas
thermo
fisher
scientif
macquari
park
nsw
australia
hepat
microsom
pool
male
cat
pool
male
beagl
purchas
bioreclamationivt
frankfurt
germani
product
number
respect
ship
liquid
nitrogen
store
prior
use
common
brushtail
possum
microsom
femal
one
male
extract
prepar
accord
hill
modifi
kimbl
et
al
prior
liver
collect
possum
euthan
pentobarbiton
human
reason
independ
studi
anim
demonstr
outward
clinic
sign
hepat
diseas
liver
appear
grossli
unremark
postmortem
examin
liver
collect
approv
univers
sydney
anim
ethic
committe
aec
protocol
commerci
procur
felin
canin
microsom
hepat
microsom
protein
concentr
mgml
common
brushtail
possum
microsom
activ
canin
felin
microsom
determin
manufactur
present
supplementari
inform
file
tabl
common
brushtail
possum
hepat
microsom
protein
concentr
measur
use
bradford
assay
kit
biorad
hercul
ca
usa
standard
bovin
serum
albumin
pool
hepat
felin
canin
microsom
contain
enzym
three
individu
phase
phase
ii
reaction
substrat
deplet
method
use
estim
vitro
cl
int
respect
microsom
protein
concentr
chosen
undertak
preliminari
assay
condit
optimis
trial
base
recommend
best
practic
microsom
experiment
incub
time
select
within
rate
deplet
linear
therefor
presum
follow
first
order
elimin
phase
hepat
microsom
assay
modifi
method
describ
kimbl
et
al
mefloquin
preincub
ml
sodium
phosphat
buffer
ph
contain
nadph
regener
system
mm
nadp
u
glucos
dehydrogenas
mm
glucos
mm
magnesium
chlorid
mgcl
open
air
shake
water
bath
five
minut
final
concentr
mefloquin
select
concentr
use
mcdonagh
et
al
fipv
infect
crandel
ree
felin
kidney
cell
enzymat
reaction
initi
ad
mgml
concentr
either
felin
canin
microsom
protein
mgml
brushtail
possum
microsom
protein
collect
microsom
enzym
cofactor
solvent
refer
matrix
incub
matrix
gentli
agit
pipett
tip
aliquot
remov
time
minut
possum
incub
aliquot
remov
minut
extract
aliquot
mix
icecold
methanol
also
contain
deactiv
reaction
reaction
deactiv
mefloquin
sampl
underw
liquidliquid
extract
wherebi
sampl
ad
ml
ethyl
acet
vortex
centrifug
g
five
minut
organ
layer
transfer
new
ml
microcentrifug
tube
dri
thermo
fisher
scientif
speed
vac
concentr
macquari
park
nsw
australia
one
hour
dri
residu
reconstitut
methanol
reconstitut
sampl
vortex
centrifug
g
five
minut
remov
particul
supernat
inject
hplc
system
sampl
run
duplic
neg
control
underw
incub
process
describ
includ
one
set
contain
incub
compon
except
substrat
anoth
set
omit
nadph
cofactor
anoth
omit
microsom
posit
control
substrat
tramadol
tramadol
incub
mgml
either
felin
microsom
canin
microsom
minut
undergo
phase
metabol
odmt
ndesmethyltramadol
ndmt
incub
canin
microsom
odmt
incub
felin
microsom
tramadol
sampl
undergo
liquidliquid
extract
intern
standard
use
phase
ii
hepat
microsom
assay
modifi
method
describ
slovak
et
al
mefloquin
final
concentr
preincub
ml
mm
potassium
phosphat
buffer
ph
contain
alamethicin
mgml
concentr
hepat
microsom
protein
either
cat
dog
common
brushtail
possum
openair
shake
water
bath
five
minut
enzymat
reaction
initi
ad
solut
consist
mm
potassium
phosphat
buffer
purifi
water
mm
udpga
ml
mm
mgcl
incub
matrix
gentli
agit
pipett
tip
aliquot
remov
time
minut
extract
aliquot
mix
icecold
methanol
also
contain
deactiv
reaction
reaction
deactiv
sampl
mefloquin
substrat
underw
liquidliquid
extract
per
phase
reaction
organ
layer
transfer
new
ml
microcentrifug
tube
dri
concentr
one
hour
dri
residu
reconstitut
methanol
reconstitut
sampl
vortex
centrifug
g
five
minut
remov
particul
supernat
inject
hplc
system
sampl
includ
control
run
duplic
neg
control
group
three
speci
utilis
incub
protocol
describ
howev
udpga
ad
matrix
posit
control
involv
deplet
odmt
tramadol
metabolit
known
odmt
glucuronid
product
recognis
phase
ii
glucuronid
reaction
gener
incub
canin
common
brushtail
possum
microsom
minim
felin
microsom
chromatograph
condit
detect
odmt
deplet
odmt
glucuronid
detect
tramadol
deplet
phase
incub
odmt
sampl
undergo
liquidliquid
extract
intern
standard
use
mefloquin
verapamil
identifi
microsom
matrix
hplc
method
modifi
gbotosho
et
al
hplc
system
consist
shimadzu
deliveri
unit
ht
degass
solvent
deliveri
unit
auto
injector
uv
detector
column
oven
shimadzu
lc
solut
softwar
kyoto
japan
use
chromatograph
control
data
collect
data
process
chromatograph
separ
perform
microsorbmv
column
mm
mm
id
varian
mulgrav
vic
australia
mm
opticguard
precolumn
choic
analyt
thornleigh
nsw
australia
pressur
psi
isocrat
mobil
phase
consist
mixtur
mm
sodium
phosphat
buffer
triethylamin
adjust
ph
acetonitril
methanol
vvv
flow
rate
mlmin
inject
volum
per
sampl
diod
array
detector
set
wavelength
nm
total
run
time
sampl
minut
retent
time
verapamil
mefloquin
minut
respect
detect
tramadol
deplet
phase
reaction
deplet
odmt
odmt
glucuronid
demonstr
phase
ii
reaction
use
hplc
system
describ
previous
chromatograph
separ
involv
luna
column
mm
x
mm
phenomenex
lane
cove
nsw
australia
mm
opticguard
precolumn
choic
analyt
thornleigh
nsw
australia
pressur
psi
ambient
room
temperatur
isocrat
mobil
phase
consist
mixtur
phosphat
buffer
acetonitril
vv
contain
triethylamin
adjust
ph
flow
rate
mlmin
inject
volum
fluoresc
detect
excit
nm
emiss
nm
use
total
run
time
sampl
minut
retent
time
odmt
tramadol
approxim
minut
respect
incub
run
duplic
singl
experi
statist
data
analysi
perform
use
graphpad
prism
softwar
graph
pad
softwar
inc
ca
usa
substrat
deplet
model
reliabl
deplet
incub
period
howev
deplet
greater
two
way
anova
perform
compar
mean
deplet
speci
timepoint
anova
signific
tukey
multipl
comparison
test
undertaken
statist
signific
accept
p
unknown
hplc
chromatogram
peak
evid
phase
mefloquin
sampl
incub
felin
microsom
consequ
sampl
rerun
captur
retent
time
peak
visualis
chromatogram
unknown
peak
hypothesis
carboxymefloquin
therefor
modifi
lcm
method
geditz
et
al
utilis
pseudotarget
approach
tri
identifi
carboxymefloquin
masstocharg
ratio
mz
valu
lcm
equip
consist
thermo
scientif
vanquish
uhplc
system
thermo
fisher
scientif
san
jose
ca
usa
connect
hybrid
quadrupol
orbitrap
mass
spectromet
equip
electrospray
ioniz
esi
sourc
thermo
scientif
q
exact
hfx
hybrid
quadrupoleorbitrap
mass
spectromet
thermo
fisher
scientif
san
jose
ca
usa
agil
zorbax
extend
column
mm
mm
id
agil
technolog
australia
mulgrav
vic
australia
use
chromatograph
separ
thermo
xcalibur
softwar
version
thermo
fisher
scientif
san
jose
ca
usa
use
instrument
control
data
process
mass
spectromet
oper
neg
ion
mode
isocrat
mobil
phase
consist
methanol
water
formic
acid
vv
run
time
minut
flow
rate
mlmin
inject
volum
column
temperatur
set
origin
techniqu
unabl
detect
carboxymefloquin
select
reaction
monitor
srm
use
identifi
carboxymefloquin
simultan
search
mz
valu
well
mz
valu
daughter
ion
fragment
lcm
equip
consist
thermo
scientif
vanquish
uhplc
system
thermo
fisher
scientif
san
jose
ca
usa
connect
tsq
alti
tripl
quadrupol
mass
spectromet
thermo
fisher
scientif
san
jose
ca
usa
earlier
pseudotarget
approach
column
use
chromatograph
separ
softwar
instrument
control
data
process
eluent
water
formic
acid
methanol
formic
acid
b
run
time
minut
method
gradient
use
min
b
min
b
isocrat
min
b
eluent
flow
rate
mlmin
inject
volum
column
temperatur
heatedelectrospray
ionis
hesi
paramet
capillari
voltag
kv
posit
mode
kv
neg
mode
sheath
ga
arbitrari
unit
auxiliari
ga
arbitrari
unit
carboxymefloquin
analys
srm
mode
v
posit
v
neg
collis
energi
srm
transit
carboxymefloquin
vitro
cl
int
estim
substrat
deplet
method
origin
describ
obach
use
vitro
halflif
approach
peak
ratio
mefloquin
set
mefloquin
likewis
peak
ratio
time
point
also
convert
percentag
remain
mefloquin
plot
natur
log
remain
drug
vs
incub
time
wherebi
slope
regress
line
repres
rate
constant
k
use
estim
vitro
k
vitro
cl
int
vitro
incub
volum
mg
protein
determin
vitro
cl
int
substrat
deplet
method
substrat
deplet
initi
valu
minut
deplet
deem
slow
measur
consequ
circumst
vitro
cl
int
could
estim
due
accuraci
precis
concern
mefloquin
phase
deplet
observ
respect
felin
brushtail
possum
microsom
canin
microsom
compar
chromatogram
mefloquin
deplet
min
microsom
neg
control
illustr
fig
mefloquin
deplet
min
incub
felin
possum
microsom
howev
signific
differ
mean
deplet
percentag
two
speci
timepoint
min
comparison
mefloquin
deplet
occur
minut
incub
canin
microsom
plo
one
fig
actual
deplet
data
provid
tabl
tramadol
posit
control
deplet
minut
incub
felin
canin
microsom
respect
appar
vitro
cl
int
mean
sd
mefloquin
pool
felin
possum
microsom
protein
respect
wherea
vitro
cl
int
mefloquin
pool
canin
microsom
could
determin
substrat
deplet
initi
valu
minut
base
condit
use
hplc
analysi
potenti
phase
metabolit
appear
felin
microsom
incub
sampl
minut
observ
canin
sampl
although
initi
lcm
pseudotarget
could
identifi
peak
srm
later
identifi
carboxymefloquin
felin
sampl
also
canin
sampl
neg
control
felin
canin
common
brushtail
microsom
mefloquin
deplet
initi
valu
time
minut
thu
slow
determin
tabl
rate
odmt
deplet
min
canin
possum
microsom
odmt
deplet
felin
microsom
detect
hplc
howev
small
odmt
glucuronid
signal
detect
felin
sampl
lcm
first
report
studi
vitro
microsom
metabol
mefloquin
felin
microsom
screen
provid
import
first
step
descript
mefloquin
pharmacokinet
pk
safeti
profil
precursor
use
antivir
drug
treatment
fip
fcv
infect
cat
mefloquin
shown
undergo
deplet
felin
possum
microsom
phase
metabol
cofactor
consist
observ
mefloquin
undergo
vitro
phase
metabol
speci
includ
human
rat
monkey
howev
mefloquin
also
demonstr
undergo
slow
phase
metabol
canin
microsom
fontain
et
al
report
mefloquin
remain
canin
sampl
fivehour
microsom
incub
wherea
close
mefloquin
metabol
via
phase
biotransform
canin
primari
hepatocyt
incub
whilst
longer
incub
sometim
requir
hour
prolong
microsom
incub
undertaken
studi
due
concern
extend
incub
time
result
declin
enzym
activ
ultim
underestim
intrins
clearanc
unchang
canin
microsom
mefloquin
deplet
percentag
greater
indic
substrat
deplet
occur
sampl
minut
although
arguabl
durat
use
studi
short
canin
microsom
incub
undertaken
minut
likewis
demonstr
mefloquin
deplet
possibl
mefloquin
deplet
may
occur
went
undetect
hplc
due
assay
insensit
use
tramadol
phase
posit
control
confirm
vitro
phase
hepat
metabol
occur
felin
canin
microsom
advantag
use
tramadol
phase
posit
control
mefloquin
tramadol
consid
undergo
phase
metabol
catalys
cytochrom
enzym
cyp
eg
subfamili
human
howev
human
tramadol
catalys
ndmt
schemat
represent
tramadol
metabol
human
liver
cell
found
http
mefloquin
report
undergo
vitro
phase
biotransform
two
major
metabolit
carboxymefloquin
primari
metabolit
hydroxymefloquin
much
lesser
degre
human
rat
monkey
dog
model
mefloquin
phase
felin
microsom
incub
gener
unknown
peak
increas
amplitud
time
peak
subsequ
identifi
srm
carboxymefloquin
also
identifi
srm
canin
incub
sampl
neg
control
carboxymefloquin
consid
metabolit
gener
felin
microsom
presenc
neg
control
phase
metabol
reaction
associ
carboxyl
like
identif
substrat
associ
mefloquin
instabl
process
mefloquin
instabl
could
explain
slight
revers
mefloquin
deplet
felin
microsom
min
incub
fig
identif
hydroxymefloquin
pursu
produc
rel
minor
amount
mz
valu
establish
studi
also
demonstr
mefloquin
appear
undergo
phase
ii
conjug
glucuronid
metabol
incub
microsom
cat
dog
common
brushtail
possum
canin
common
brushtail
possum
microsom
incub
use
posit
control
phase
ii
reaction
shown
deplet
odmt
odmt
glucuronid
studi
support
hypothesi
phase
ii
conjug
metabol
may
rout
mefloquin
metabol
speci
fontain
et
al
dismiss
contribut
phase
ii
conjug
glucuronid
biotransform
mefloquin
none
unidentifi
mefloquin
metabolit
produc
dog
rat
monkey
hepatocyt
studi
hydrolys
therefor
like
mefloquin
undergo
phase
ii
conjug
glucuronid
present
issu
associ
administr
drug
undergo
rout
metabol
cat
eg
acetaminophenparacetamol
vitro
metabol
model
microsom
incub
invalu
screen
tool
use
prior
undertak
vivo
studi
speci
vivo
pharmacokinet
profil
drug
unknown
exampl
microsom
incub
model
provid
inform
parent
drug
rate
metabol
well
inform
metabolit
howev
microsom
contain
phase
drug
metabolis
enzym
dme
cyp
flavincontain
monooxygenas
phase
ii
ugt
therefor
repres
entir
spectrum
dme
consequ
experi
requir
elucid
mefloquin
elimin
pathway
microsom
assay
use
limit
exampl
pool
microsom
use
speci
wherebi
three
individu
repres
pool
although
uncommon
practic
use
pool
microsom
may
overlook
differ
one
individu
metabol
capac
moreov
phase
ii
metabol
studi
phosphat
buffer
ph
use
describ
slovak
et
al
howev
use
tri
buffer
oppos
phosphat
buffer
shown
lead
increas
activ
ugt
incub
human
liver
microsom
yet
compar
speci
microsom
studi
use
phosphat
buffer
littl
consequ
unless
speci
significantli
differ
concentr
andor
activ
hepat
ugt
furthermor
contrast
common
brushtail
possum
microsom
harvest
author
felin
canin
microsom
purchas
europ
sinc
could
sourc
local
although
qualiti
control
inform
concern
activ
variou
substrat
provid
manufactur
result
may
differ
microsom
three
speci
underw
extract
transport
storag
condit
final
canin
felin
microsom
contain
contribut
male
subject
activ
recogn
differ
activ
substrat
sex
depend
therefor
research
evalu
sex
differ
substrat
intrins
clearanc
may
requir
mefloquin
recognis
result
varieti
side
effect
multipl
human
bodi
system
includ
psychiatr
gastrointestin
cardiovascular
haematolog
dermatolog
manifest
mefloquin
use
antivir
cat
futur
studi
indic
cautiou
administr
warrant
felin
patient
degre
liver
dysfunct
given
liver
primari
site
phase
metabol
mefloquin
antimalari
vivo
human
pk
profil
known
mefloquin
metabolit
excret
slowli
bodi
faec
urin
termin
elimin
halflif
roughli
three
week
healthi
subject
day
malaria
patient
uncompl
falciparum
malaria
approxim
day
case
involv
sever
malaria
report
use
veterinari
medicin
antimalari
drug
raptor
howev
mefloquin
exact
mechan
action
antimalari
agent
andor
antivir
agent
unknown
recent
antivir
develop
shown
safe
efficaci
fipv
natur
experiment
infect
cat
one
agent
broad
spectrum
coronaviru
proteas
inhibitor
adenosin
nucleosid
analogu
howev
neither
antivir
obtain
registr
veterinari
use
consequ
remain
import
investig
readili
avail
drug
mefloquin
antifipv
activ
urgent
requir
invari
fatal
diseas
vitro
studi
provid
inform
mefloquin
hepat
metabol
cat
indic
result
delay
metabol
cat
studi
undertaken
describ
mefloquin
pk
profil
cat
well
efficaci
treat
fipv
fcv
infect
cat
support
inform
